Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CEFTRIAXONE DISODIUM

All injection strengths: general benefit

Other products in the same Health Canada class (J01D, J01DD) — coverage varies; not interchangeable

  • Cefixime (Suprax): general benefit
  • Cefadroxil (Duricef): general benefit, Not a benefit
  • Cefprozil (Ran-Cefprozil): general benefit, Not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, Not a benefit
  • Cephalexin (Ceporex): general benefit, Not a benefit
  • Cefazolin (Cefazolin for Injection): not a benefit

1 more in the class list below

Ceftriaxone for Injection · DIN 02289709 · 2g/Vial · powder for injection, vial

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ceftriaxone for Injection · DIN 02289709 Manufacturer: Fresenius Kabi Canada Ltd.; listing date 2025-03-31 Health Canada: Marketed since 2024-08-15 · brand CEFTRIAXONE FOR INJECTION · ATC J01DD04 CEFTRIAXONE · form Powder for solution · route Intravenous, Intramuscular · ingredients CEFTRIAXONE (CEFTRIAXONE SODIUM) 2 G/VIAL · company Fresenius kabi canada ltd · schedule Prescription
Check this DIN again · Health Canada product record

Ceftriaxone for Injection: Formulary list price $24.1395/unit (unit not stated in source; not the patient's cost)

Ministry pays: $24.1395 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77504 · Verify on the e-Formulary ↗ (DIN 02289709)

Source record
DIN 02289709: Ceftriaxone for Injection Raw flags: sec3=Y Item: 081228046; group id 41; item number 0089; lccId None; manufacturer id FKC Source form: Inj Pd-Vial Pk; strength: 2g/Vial Recorded listing: General benefit Source prices (unrounded): $24.1395; ministry $24.1395 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02289709 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77504
Interchangeable products
Ceftriaxone · DIN 02292289 · $24.1395 Ceftriaxone Sodium For Injection BP · DIN 02325624 · $24.1395 Rocephin · DIN 00657409 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CEFIXIME, CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, CLINDAMYCIN PHOSPHATE, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFIXIME

· 4 products · General benefit · strengths: 20mg/mL, 400mg · Oral Susp, Tab

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CLINDAMYCIN HCL

· 20 products · Listed, not a benefit (2), General benefit (18) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

CLINDAMYCIN PHOSPHATE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 300mg/2mL · Inj Sol-2mL Pk

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: bone and joint infections, intra-abdominal infections, lower respiratory tract infections, skin and skin structure infections, urinary tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFOXITIN SODIUM · Off-Formulary Interchangeable, not an ODB benefit 1 - Intra-abdominal infections such as peritonitis and intra-abdominal abscess PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 4 - Urinary tract infections (including those caused by Serratia marcescens and Serratia spp.) PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 5 - Lower respiratory tract infections PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph 6 - Bone and joint infections caused by Staphylococcus aureus PM: https://pdf.hres.ca/dpd_pm/00073366.PDF; date November 16, 2023; DIN 02128187; fetched 2026-09-10 Product monograph CLINDAMYCIN PHOSPHATE · General benefit (1), Listed, not a benefit (1) • Skin and skin structure infections including cellulitis, abscesses, and wound infections when caused by Streptococcus pyogenes, Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Intra-abdominal infections including peritonitis and abdominal abscess when caused by susceptible anaerobes. Clindamycin should be given in conjunction with an antibiotic of appropriate gram negative aerobic spectrum. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph • Bone and joint infections including osteomyelitis and septic arthritis when caused by sensitive strains of Staphylococcus aureus and anaerobes. PM: https://pdf.hres.ca/dpd_pm/00085906.PDF; date AUG 27, 2026; DIN 02230540; fetched 2026-09-10 Product monograph AMOXICILLIN & CLAVULANIC ACID · General benefit (22), Listed, not a benefit (3) • Lower Respiratory Tract Infections when caused by β-lactamase producing strains of H. influenzae, K. pneumoniae, S. aureus or Moraxella (Branhamella) catarrhalis. PM: https://pdf.hres.ca/dpd_pm/00084428.PDF; date 2026-04-24; DIN 01916874; fetched 2026-09-10 Product monograph CEFADROXIL · Listed, not a benefit (1), General benefit (3) • Skin and skin structure infections caused by Staphylococcus aureus and/or Group A ß– hemolytic streptococci. PM: https://pdf.hres.ca/dpd_pm/00056563.PDF; date May 20, 2020; DIN 02235134; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Ceftriaxone for Injection is indicated for the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph. aureus, Strep. pneumoniae and species (excluding enterococci). • Urinary tract infections (complicated and uncomplicated) caused by E. coli, Klebsiella species, P. mirabilis and P. vulgaris. • Bacterial Septicemia caused by E. coli, H. influenzae, K. pneumoniae, Staph. aureus and Strep. pneumoniae, (excluding enterococci). • Skin and Skin Structure Infections caused by K. pneumoniae and species, P. mirabilis, Staph. aureus, Staph. epidermidis and Streptococcus species (excluding enterococci). • Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae and Streptococcus species (excluding enterococci). • Intra-Abdominal Infections caused by E.coli and K. pneumoniae. • Meningitis caused by H. influenzae, N. meningitidis, and Strep. pneumoniae. Ceftriaxone sodium should not be used for the treatment of meningitis caused by L. monocytogen… https://pdf.hres.ca/dpd_pm/00071552.PDF PM date: MAY 15, 2023 Source product: CEFTRIAXONE FOR INJECTION; DIN 02289695; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.